Rare Bleeding Disorders
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Communication Preferences
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Communication Preferences
    • Sign Out
    Medical Information
    Non-US Health Care Professionals
Rebinyn® coagulation factor IX (recombinant), glycoPEGylated logo
Important Safety Information | Patient Site
Prescribing Information
    • How it Works
    • Patient Use Cases
    • Efficacy
    • Safety Profile
    • Pharmacokinetics
    • FIX PK Comparisons
    • Comparative Modeling
    • Simplified Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
Rebinyn® coagulation factor IX (recombinant), glycoPEGylated logo

Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes and perioperative management of bleeding.

Prescribing Information
Important Safety Information | Patient Site

Education for your patients

Novo Nordisk helps support your patients with resources and tools for success, right from the start. Educational materials are available to download, share, or for delivery to your office. 

Jason playing soccer

Education for your patients

Novo Nordisk helps support your patients with resources and tools for success, right from the start. Educational materials are available to download, share, or for delivery to your office. 

Leopoldo playing soccer

Share these resources with your patients

Rebinyn® Patient Brochure
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® Patient Brochure
A resource with information on the half-life and additional features of Rebinyn®, with product comparisons and more.
Download
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Rebinyn® MixPro® Reconstitution Video
(9:50)
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® MixPro® Reconstitution Video
An overview for patients that describes how to reconstitute a dose of Rebinyn® with MixPro®.
Watch video
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Rebinyn® Meet Abdiel
(9:41)
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® Meet Abdiel
Abdiel, who lives with hemophilia B, shares his story of empowering others in the hemophilia community, as well as why he chose to use Rebinyn®.
Watch video
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Rebinyn® Meet Emili
(10:37)
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® Meet Emili
Emili, a caregiver for her young son Xander, shares why she chose Rebinyn® to treat his hemophilia B.
Watch video
Prescribing Information | Important Safety Information
Prescribing Information | Important Safety Information
Rebinyn® Meet Markus
(3:50)
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® Meet Markus
Markus, who is 33 years old and lives with hemophilia B, shares his love of the outdoors.
Watch video
Prescribing Information | Important Safety Information
website
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Rebinyn® Patient Website
Patients can learn more about Rebinyn®, including reasons to consider Rebinyn® and how it works.
Visit website
Prescribing Information | Important Safety Information

Materials available through your Novo Nordisk Representative

The following items are available by contacting your representative:

Patient Welcome Kit

Patient Welcome Kit

This kit is designed to help patients get started with Rebinyn®. It includes educational resources, such as a Quick Start Guide, Infusion Logbook, a calendar, and a tourniquet—all in a zippered carrying bag.

Travel Case

Travel Case

This portable, reusable travel case makes it possible for your patients to store supplies at home or while traveling.

To request a welcome kit or a travel case for your patient, please contact your representative.

Education for you

Novo Nordisk provides educational materials for professionals who treat patients with hemophilia B.

View materials
Healthcare professionals

Patient advocacy groups

Hemophilia Federation of America (HFA)

Hemophilia Federation of America (HFA)

Connecting people affected by bleeding disorders to others in their community, while advocating for the development of safe, affordable treatment options. Get more info at hemophiliafed.org   

National Hemophilia Foundation (NHF)

National Hemophilia Foundation (NHF)

The largest nonprofit organization dedicated to education, advocacy, and research of inheritable bleeding disorders. Direct patients to find resources at hemophilia.org  

World Federation of Hemophilia (WFH)

World Federation of Hemophilia (WFH)

Committed to improving and sustaining excellent care for people with bleeding disorders across the world. Help patients learn more about the WFH by sending them to wfh.org

The Coalition for Hemophilia B

Coalition for Hemophilia B

The Coalition for Hemophilia B aims to make quality of life the focal point of treatment for individuals with hemophilia B in the 21st century. For more information, send patients to hemob.org   

Selected Important Safety Information for Rebinyn®

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic type reactions occur and initiate appropriate treatment.

Indications and Usage

Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes and perioperative management of bleeding.

Limitations of Use: Rebinyn® is not indicated for routine prophylaxis or for immune tolerance induction in patients with hemophilia B.

Important Safety Information

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic-type reactions occur and initiate appropriate treatment.
  • Development of neutralizing antibodies (inhibitors) to Factor IX may occur. Monitor patients for development of factor IX inhibitors if bleeding is not controlled with the recommended dose of Rebinyn® or if expected Factor IX activity plasma levels are not attained. Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used.
  • The use of Factor IX-containing products has been associated with thrombotic complications. Monitor for thrombotic and consumptive coagulopathy when administering Rebinyn® to patients with liver disease, post-operatively, to newborn infants, or to patients at risk of thrombosis or disseminated intravascular coagulation (DIC).
  • Nephrotic syndrome has been reported following immune tolerance induction therapy with Factor IX products in hemophilia B patients with Factor IX inhibitors, often with a history of allergic reactions to Factor IX. The safety and efficacy of using Rebinyn® for immune tolerance induction have not been established.

Adverse Reactions

  • The most common adverse reactions reported in clinical trials (≥1%) were itching and injection site reactions.
  • Animals administered repeat doses of Rebinyn® showed accumulation of PEG in the choroid plexus. The potential clinical implications of these animal findings are unknown.

Please click here for Rebinyn® Prescribing Information.

Rare Bleeding Disorders
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

Rebinyn® and MixPro® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2021 Novo Nordisk All rights reserved.  US21REB00006 November 2021

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials